(http://www.crncc.nihr.ac.uk/about_us/ccrn/ specialty).
The CRN is responsible for a database known as the NIHR CRN portfolio (http:// www.crncc.nihr.ac.uk/about_us/processes/ portfolio), a collection of high-quality clinical studies, many of which are randomised controlled trials. Only studies included, termed 'adopted', in this database have access to infrastructure and NHS service support costs. Studies are automatically eligible for inclusion on the national portfolio if they are funded by NIHR, other areas of government, or NIHR noncommercial partners. These non-commercial partners are organisations that (i) award funds as a result of open national competition with high-quality peer review, (ii) fund research that is of clear benefit to the NHS, and (iii) have a strategic direction for the research they fund that takes into account Department of Health and NHS priorities and needs. Other studies require formal consideration to be adopted onto the national portfolio and include (i) studies that are industry supported and sponsored, (ii) studies that are industry supported but not sponsored (investigator-led collaborations), and (iii) studies funded by overseas agencies (eg National Institutes of Health or European Union Framework Programmes).
The CRN has set several high-level objectives (http://www.crncc.nihr.ac.uk/about_us/ performance_objectives), which act as a management mechanism to drive forward performance by setting defined and agreed criteria for gauging improvement over time. These objectives are focused on delivery outcomes with specific objectives for 2010-2015 that include: This is particularly important for researchers working on commercial life-sciences studies, given that the United Kingdom must compete with other countries to host studies that could benefit NHS patients. The practical support involves reducing the bureaucracy involved with setting up studies and the funding of the research and facilities such that they do not drain core NHS resources. By supporting research posts and costs, a much wider range of NHS trusts are now involved, when previously research was the preserve of large teaching hospitals. Consequently, many more patients across England are aware of and have increased access to clinical studies. This development may 
458
Eye result in better health outcomes, as suggested by some studies where patients cared for in research-active institutions have been reported as having better outcomes than those cared for in a non-research environment. 2 To assist with the CRN's objectives, a series of national specialty groups were set up, one of which is the Ophthalmology Specialty Group (OSG) (http:// www.crncc.nihr.ac.uk/about_us/ccrn/specialty/ ophthalmology/ophthalmology.htm). The OSG has wide geographical coverage, with 22 of the 25 comprehensive local research networks (CLRNs) having nominated a lead in this specialty group area, and nominated leads for Wales, Scotland, and Northern Ireland (Figure 1 ).
Clinicians interested in NHS research in Ophthalmology or allied fields are encouraged to seek out their local OSG leads, as there is considerable variability in funding streams and funding allocations in each of the regions. The OSG has several roles, which include the provision of early advice on whether a potential study, either commercial or non-commercial, will be supported by the clinical community and is achievable within the NHS. Additionally, the group offers detailed advice on feasibility, such as potential numbers of investigators and patients in each site. Members of the OSG do this by providing input to adoption committees, both for commercial trials and for non-commercial trials, which are not automatically eligible for the portfolio.
As of 23 May 2012, there were a total of 1763 open studies (open to recruitment) on the portfolio, of which 93 (5.3%) were led (the primary topic of interest being Ophthalmology) and 12 co-supported (where Ophthalmology specialists have an influence on patient recruitment).
Since the development of the CLRN infrastructure, there has been a progressive increase in the number of studies, as shown in Figure 2 when planning studies. Of the open studies, 14 (15%) were commercial and 79 (85%) non-commercial; the breakdown by disease group is presented in Table 1 .
Considering the types of study open on 23 May 2012, 18% were clinical trials involving medicinal products as interventions in diseases of the eye and optic nerve, 7% involved the study of devices in diseases of the eye and optic nerve, 11% were studies and trials of childhood visual disorders, 3% were longitudinal observational studies or those documenting natural history, 26% investigated the risk factors, genetics, and pharmacogenomics of eye diseases, and 10% were clinical trials involving surgical interventions.
The numbers of NHS patients participating in clinical research in England has greatly increased since the new infrastructure has been implemented, with the NIHR achieving one of its goals of doubling the number of participants recruited into NIHR CRN portfolio studies.
Along with other stakeholders, such as the Royal College of Ophthalmologists, the OSG is working to ensure that new developments in the field of Ophthalmology research are supported by an ongoing stream of clinically relevant research studies, which can be feasibly delivered in the NHS setting.
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